Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-12
2007-06-12
McKenzie, Thomas (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S355000, C514S356000, C546S257000, C546S272100, C546S316000, C544S333000
Reexamination Certificate
active
11397743
ABSTRACT:
The present invention relates to compounds of the formulawherein X and R1to R8are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity.
REFERENCES:
patent: 3940418 (1976-02-01), Hamilton
patent: 5462960 (1995-10-01), Barth et al.
patent: 5596106 (1997-01-01), Cullinan et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5756524 (1998-05-01), Riordan et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6355631 (2002-03-01), Achard et al.
patent: 6479479 (2002-11-01), Achard et al.
patent: 6509367 (2003-01-01), Martin et al.
patent: 6518264 (2003-02-01), Achard et al.
patent: 6566356 (2003-05-01), Achard et al.
patent: 6734176 (2004-05-01), Achard et al.
patent: 6858603 (2005-02-01), Achard et al.
patent: 6872717 (2005-03-01), Achard et al.
patent: 2001/0027193 (2001-10-01), Achard et al.
patent: 2002/0019383 (2002-02-01), Achard et al.
patent: 2002/0035102 (2002-03-01), Achard et al.
patent: 2003/0055033 (2003-03-01), Achard et al.
patent: 2003/0119810 (2003-06-01), Achard et al.
patent: 2003/0162808 (2003-08-01), Achard et al.
patent: 2004/0157823 (2004-08-01), Achard et al.
patent: 2004/0235816 (2004-11-01), Achard et al.
patent: 2004/0259887 (2004-12-01), Dow
patent: 2005/0130953 (2005-06-01), Achard et al.
patent: 576357 (1993-12-01), None
patent: 656354 (1995-06-01), None
patent: 658546 (1995-06-01), None
patent: 2783246 (2000-03-01), None
patent: 2805810 (2001-09-01), None
patent: 2805817 (2001-09-01), None
patent: 2805818 (2001-09-01), None
patent: 2856684 (2004-12-01), None
patent: WO 96/02248 (1996-02-01), None
patent: WO 97/19063 (1997-05-01), None
patent: WO 98/031227 (1998-07-01), None
patent: WO 98/041519 (1998-09-01), None
patent: WO 98/043635 (1998-10-01), None
patent: WO 98/043636 (1998-10-01), None
patent: WO 00/15609 (2000-03-01), None
patent: WO 00/46209 (2000-08-01), None
patent: WO 01/32663 (2001-05-01), None
patent: WO 01/64632 (2001-09-01), None
patent: WO 01/64633 (2001-09-01), None
patent: WO 01/64634 (2001-09-01), None
patent: WO 01/70700 (2001-09-01), None
patent: WO 02/28346 (2002-04-01), None
patent: WO 03/051850 (2003-06-01), None
patent: WO 03/051851 (2003-06-01), None
patent: WO 03/082191 (2003-10-01), None
patent: WO 03/084930 (2003-10-01), None
patent: WO 2004/110453 (2004-12-01), None
patent: WO 2004/111033 (2004-12-01), None
patent: WO 2004/111034 (2004-12-01), None
patent: WO 2004/111038 (2004-12-01), None
patent: WO 2004/111039 (2004-12-01), None
D.Shire, et al., J. Biol. Chem. 270 (8) (1995) 3726-31.
E. Ryberg, et. al., FEBS Lett. 579 (2005) 259-264.
S. Munro, et. al., Nature 365 (1993) 61-61.
Y. Gaoni, et. al., J. Am. Chem. Soc., 86 (1964) 1646).
R. G. Pertwee, Pharmaceut. Sci. 3 (11) (1997) 539-545.
E. M. Williamson, F. J. Evans, Drugs 60 (6) (2000) 1303-1314.
R.G. Pertwee, Curr. Med. Chem., 6 (8) (1999) 635-664.
W.A. Devane, et. al., Science 258 (1992) 1946-9.
V. Di Marzo, et. al., Trends in Neuroscience 21 (12) (1998) 521-8.
A. C. Porter, C.C. Felder, Pharmacol. Ther., 90 (1) (2001) 45-60.
C.M. Williams, et. al., Psychopharmacology 143 (3) (1999) 315-317.
C. C. Felder, et. al., Proc. Natl. Acad. Sci. U. S. A. 90 (16) (1993) 7656-60).
G. Colombo, et. al., Life Sci. 63 (8) (1998) L113-PL117.
V. Di Marzo, S. K. Goparaju, L. Wang, J. Liu, S. Bitkai, Z. Jarai, F. Fezza, G. I. Miura, R. D. Palmiter, T. Suguira, G. Kunos, Nature 410 (6830) 822-825.
F. Barth, et. al., “Cannabinoid antagonists: From research tools to potential new drugs.” Abstracts of Papers, 222nd ACS National Meeting, Chicago, IL, United States, Aug. 26-30, 2001.
AAI; M. Pacheco, S. R. Childers, R. Arnold, F. Casiano, S. J. Ward, J. Pharmacol. Exp. Ther. 257 (1) (1991) 170-183.
F. M. Casiano, et. al., NIDA Res. Monogr. 105 (1991) 295-6.
K. Hosohata, et. al., Life Sci. 61 (1997) 115-118.
R. Pertwee, et. al., Life Sci. 56 (23-24) (1995) 1949-55.
C. C. Felder, et. al., J. Pharmacol. Exp. Ther. 284 (1) (1998) 291-7.
M. Kanyonyo, et. al., Bioorg. Med. Chem. Lett. 9 (15) (1999) 2233-2236.
F. Ooms, et. al., J. Med. Chem. 45 (9) (2002) 1748-1756.
R. Mechoulam (Ed.)in “Cannabinoids as therapeutic Agents”, 1986, pp. 1-20, CRC Press.
Hebeisen Paul
Iding Hans
Nettekoven Matthias Heinrich
Obst Ulrike
Roever Stephan
Hoffmann-La Roche Inc.
Johnston George W.
McKenzie Thomas
Megerditchian Samuel H.
Robinson Binta
LandOfFree
Pyridine-3-carboxamide derivatives as CB1 inverse agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridine-3-carboxamide derivatives as CB1 inverse agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridine-3-carboxamide derivatives as CB1 inverse agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3846408